Be Well Medical Center | Berkley, MI

Research site

(Unclaimed)

Location

1964 11 Mile Road, Berkley, Michigan, United States of America

Site insights

Top conditions

Top treatments

Emtricitabine

Lenacapavir

Tenofovir Alafenamide

Bictegravir

Tenofovir Disoproxil Fumarate

TAF

TDF

Rilpivirine

Ritonavir

Islatravir

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 49 total trials

A Clinical Trial of STP0404 in Adults With HIV-1 Infection

The purpose of this study is to evaluate the antiviral effect, safety, tolerability, and pharmacokinetics of STP0404 in adult participants living wit...

Enrolling

HIV-1-infection

Drug: High-dose STP0404 (Pirmitegravir)

Drug: Low-dose STP0404 (Pirmitegravir)

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavi...

Active, not recruiting

HIV Infection

Drug: Lenacapavir Injection

Drug: Lenacapavir Tablet

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)

The primary objectives of this study are to evaluate the antiretroviral activity of a switch to Doravirine/Islatravir (DOR/ISL) compared with continu...

Active, not recruiting

HIV-1 Infection

Drug: BIC/FTC/TAF

Drug: DOR/ISL

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of do...

Active, not recruiting

HIV-1 Infection

Drug: BIC/FTC/TAF

Drug: Placebo to DOR/ISL

Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV

The primary objective of this study is to evaluate the efficacy of oral weekly islatravir (ISL) in combination with lenacapavir (LEN) in virologicall...

Active, not recruiting

HIV-1 Infection

Drug: ISL/LEN FDC

Drug: B/F/TAF

Status recently updated

Study of GS-1219 in Participants With HIV-1

This study is part of a master study. The goal of master protocol (GSUS-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that...

Enrolling

Active, not recruiting

HIV-1-infection

Drug: BVY

Drug: GS-1219

Study of GS-3242 in Participants With HIV-1

This study is part of a master study. The goal of master protocol (GS-US-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that...

Enrolling

HIV-1-infection

Drug: Standard of Care

Drug: GS-3242

Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)

The goal of this clinical study is to learn more about the study drug lenacapavir (LEN), safety, tolerability, and pharmacokinetics (how LEN is absor...

Enrolling

HIV Pre-exposure Prophylaxis

Drug: Lenacapavir Tablet

Drug: Lenacapavir Injection

Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection (PURPOSE 2)

The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) in preventing HIV infection, in participants ≥ 16 years of a...

Active, not recruiting

Pre-Exposure Prophylaxis of HIV Infection

Drug: Sub-cutaneous (SC) Lenacapavir (LEN)

Drug: PTM Oral LEN

Locations recently updated

Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed (WONDERS1)

The goal of this clinical study is to learn more about the experimental drugs GS-1720 and GS-4182; to compare the combination of GS-1720 and GS-4182...

Active, not recruiting

HIV-1-Infection

Drug: Placebo to Match BVY

Drug: Placebo to Match GS1720/GS-4182 FDC

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1 (ISLEND-1)

The goal of this clinical study is to learn about the safety and efficacy of switching to once weekly tablet of islatravir/lenacapavir (ISL/LEN) regi...

Active, not recruiting

HIV-1-infection

Drug: B/F/TAF

Drug: PTM ISL/LEN

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (ISLEND-2)

The goal of this clinical study is to learn more about the safety and efficacy of switching to a once weekly tablet of islatravir/lenacapavir (ISL/LE...

Active, not recruiting

HIV-1-Infection

Drug: Antiretroviral Combinations

Drug: ISL/LEN

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus...

Active, not recruiting

HIV-1-infection

Drug: Stable Baseline Regimen

Drug: Bictegravir

Locations recently updated

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (CAPELLA)

The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing re...

Active, not recruiting

HIV-1-infection

Drug: Optimized Background Regimen (OBR)

Drug: Oral Lenacapavir Placebo

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms